Mode
Text Size
Log in / Sign up

Systematic review finds gut microbiota drugs reduce liver enzymes in MASLD patients compared to placeboNew drugs targeting gut bacteria may finally treat fatty liver disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider that probiotics, prebiotics, and antibiotics may reduce ALT levels in MASLD, though safety data are not reported.

This systematic review and network meta-analysis examined the efficacy of gut microbiota-regulating drugs in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study synthesized evidence from 1,511 patients comparing interventions such as probiotics, prebiotics, synbiotics, antibiotics, and postbiotics against placebo or usual care. Primary outcomes focused on liver enzymes and hepatic steatosis, while secondary outcomes included lipid markers and inflammatory cytokines.

The analysis demonstrated significant reductions in alanine aminotransferase (ALT) levels with probiotics (MD: -7.51), prebiotics (MD: -13.64), and antibiotics (MD: -24.30) relative to placebo. Similarly, aspartate aminotransferase (AST) levels decreased with probiotics (MD: -6.42) and synbiotics (MD: -13.13). Gamma-glutamyl transferase (GGT) levels declined with synbiotics (MD: -12.40), and controlled attenuation parameter (CAP) levels showed a significant reduction with synbiotics (MD: -45.69).

No statistically significant differences were observed between probiotics and synbiotics regarding lipid markers or inflammatory cytokines. The authors noted that adverse events, serious adverse events, discontinuations, and tolerability were not reported. Consequently, the certainty regarding safety and the clinical relevance of these findings remain uncertain due to the lack of reported safety data.

Imagine waking up with a heavy feeling in your stomach. You try to eat better and move more, but the weight stays, and the liver gets fatter. This is metabolic dysfunction-associated steatotic liver disease, or MASLD. It is a growing problem that affects millions of people worldwide.

For too long, doctors have told patients to just change their habits. But what if the problem is not just what you eat, but who lives inside your gut?

A New Target For Old Problems

Current treatments for fatty liver disease are very limited. Most doctors rely on diet and exercise. While these are good, they are hard to stick with. Many patients feel frustrated because their efforts do not always lead to better health.

But here is the twist. Recent science suggests the answer might lie in the trillions of tiny organisms living in your intestines. These are called gut bacteria. They act like a second brain for your body, influencing how you digest food and how your liver works.

How The Gut Talks To The Liver

Think of your gut bacteria as a busy factory floor. Sometimes, this factory gets messy. Bad bacteria can create inflammation, which is like a fire alarm going off in your body. This alarm travels to your liver, telling it to work harder and store more fat.

When you take certain drugs, they act like a cleaning crew. They help fix the factory floor. By changing the mix of bacteria, these drugs stop the fire alarm from ringing. This gives your liver a chance to rest and heal itself without needing extreme diet changes.

Scientists looked at many different studies to see if these gut-targeting drugs work. They found that 27 studies involving over 1,500 people showed clear results.

When people took probiotics, which are friendly bacteria, their liver enzyme levels dropped significantly. These enzymes are markers that tell doctors if the liver is under stress. Lower levels mean less damage.

Prebiotics, which are food for good bacteria, also helped lower these stress markers. Even antibiotics, which kill bad bacteria, showed some benefit in reducing liver stress.

The Best Combination

The most interesting finding came from using a mix of probiotics and prebiotics. This combination is called a synbiotic. It worked better than either alone.

Patients taking synbiotics saw a big drop in a specific liver measurement called the controlled attenuation parameter. This measurement tells doctors how much fat is in the liver. A lower number means a healthier liver.

But There's A Catch

While the results for liver health were great, the drugs did not change blood fat levels like cholesterol or triglycerides. They also did not immediately stop all inflammation in the blood. This means these drugs are specifically for the liver, not for fixing every heart or blood vessel issue at once.

What Experts Say

Researchers agree that this is a major step forward. For years, there were no real drugs to treat the liver itself. Now, we have tools that target the root cause in the gut.

This does not mean this treatment is available yet. The drugs are still being studied to ensure they are safe for everyone.

If you have been told to lose weight but cannot, this news brings hope. It suggests that medicine can help where willpower alone fails. You should talk to your doctor about whether these new options might be right for you.

However, do not stop your current diet or exercise plan. These new drugs are meant to work alongside healthy habits, not replace them.

This research is just the beginning. More trials are needed to see if these drugs work for everyone. Scientists will also need to figure out the best way to take them.

It will take time before these medicines are in every pharmacy. But the path is clear. By understanding our gut, we are finally finding a new way to heal the liver.

Study Details

Study typeMeta analysis
Sample sizen = 1,511
EvidenceLevel 1
PublishedJan 2026
View Original Abstract ↓
OBJECTIVE: Currently, effective drugs for metabolic dysfunction-associated steatotic liver disease (MASLD) are limited, with treatment primarily focusing on diet and exercise. Recent studies suggest that gut microbiota-regulating drugs may offer therapeutic benefits. Therefore, our aim is to evaluate the efficacy of these medications in MASLD patients. METHODS: This systematic review and network meta-analysis involved a search of PubMed, Web of Science, Embase, Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) published from January 1, 2012, to January 28, 2026. The intervention measures encompassed probiotics, prebiotics, synbiotics, antibiotics, postbiotics, and a combination of antibiotics and gut microbiota-regulating drugs. The control group received a placebo or usual care. The risk of bias in the included research was evaluated utilizing the revised Cochrane risk of bias tool for randomised trials. The confidence of evidence will be evaluated through the CINeMA (Confidence in Network Meta-Analysis) web application. Liver enzymes and hepatic steatosis were taken as the primary outcome and were analyzed by random-effects, Bayesian network meta-analyses. A two stage network meta-analysis harnessing the surface under the cumulative ranking curve (SUCRA) was performed for assessing the comparative efficacy of medications classes and particular gut microbiota-regulating drugs. The study was registered on PROSPERO: CRD42024606333. RESULTS: A total of 27 studies comprising 1,511 participants were included in this meta-analysis. Relative to placebo, reductions in alanine aminotransferase (ALT) levels were observed with probiotics (Mean Difference (MD): -7.51, 95% credible intervals (CI) [-12.36 to -2.66]), prebiotics (MD: -13.64, 95% CI [-27.07 to -0.22]) and antibiotics (MD: -24.30, 95% CI [-47.02 to -1.58]). Probiotics (MD: -6.42, 95% CI [-11.91 to -0.92]) and synbiotics (MD: -13.13, 95% CI [-20.82 to -5.45]) were both associated with a reduction in aspartate aminotransferase (AST) levels compared to placebo. Declines in gamma-glutamyl transferase (GGT) levels (MD: -12.40, 95% CI [-23.13 to -1.68]) were observed with synbiotics compared to the placebo. Additionally, synbiotics significantly reduced controlled attenuation parameter (CAP) levels compared with placebo (MD: -45.69, 95% CI [-56.39 to -34.99]). However, no statistically significant differences were observed between probiotics and synbiotics with respect to lipid markers total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), or inflammatory cytokines tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). CONCLUSIONS: Probiotics and synbiotics significantly improve liver enzymes and hepatic steatosis in patients with MASLD.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.